GLP1R and diabetes mellitus: Given that contemporary diabetes management has evolved with the advent of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors, it is beneficial to continuously update evidence that may guide modern pharmacologic control [27].